Press Releases Enlivex Therapeutics Ltd. Deutsche Boerse AG

Equities

1BT

IL0011319527

Market Closed - Deutsche Boerse AG Other stock markets 02:01:06 2024-07-11 am EDT			5-day change	1st Jan Change
1.26 ^EUR	+2.44%		+7.69%	-45.22%

Jun. 30	Enlivex Therapeutics Ltd.'s Equity Buyback announced on August 30, 2023 has expired.	CI
Jun. 24	Enlivex Therapeutics Says First Patient Dosed in Phase 1/2 Thumb Osteoarthritis Trial	MT

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Enlivex Therapeutics : Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating Allocetra in up to 46 Patients with Thumb Osteoarthritis	Jun. 24	PU
Enlivex Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating AllocetraTM in up to 46 Patients with Thumb Osteoarthritis	Jun. 24	GL
Enlivex Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating AllocetraTM in up to 46 Patients with Thumb Osteoarthritis	Jun. 24	AQ
Join Enlivex Therapeutics’ Chief Executive Officer for a Live Investor Webinar and Q&A Session on June 25	Jun. 20	GL
Join Enlivex Therapeutics’ Chief Executive Officer for a Live Investor Webinar and Q&A Session on June 25	Jun. 20	AQ
Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee Osteoarthritis	Jun. 17	GL
ENLIVEX THERAPEUTICS : CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF MARCH 31, 2024 AND DECEMBER 31, 2023 AND FOR THE THREE MONTH PERIODS ENDED MARCH 31, 2024 AND 2023 ENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF MARCH 31, 2024 AND DECEMBER 31, 2023 AND FOR THE THREE MONTH PERIODS ENDED MARCH 31, 2024 AND 2023 INDEX TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Form 6 K	Jun. 14	PU
Enlivex Receives Regulatory Authorization for the Initiation of a Placebo-Controlled Phase I/II Trial Evaluating Allocetra in Up To 46 Patients with Thumb Osteoarthritis	Jun. 03	GL
Enlivex Receives Regulatory Authorization for the Initiation of a Placebo-Controlled Phase I/II Trial Evaluating Allocetra in Up To 46 Patients with Thumb Osteoarthritis	Jun. 03	AQ
Enlivex Therapeutics : Immediate Report	May. 29	PU
Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering	May. 29	GL
Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering	May. 28	GL
Enlivex Therapeutics : Report of Periodic or Interim Report	Apr. 30	PU
Enlivex CEO Issues Letter to Shareholders – Perspectives on Recent Events	Apr. 29	GL
Enlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra™ in Patients with Knee Osteoarthritis	Apr. 22	GL
Enlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra™ in Patients with Knee Osteoarthritis	Apr. 22	AQ
Enlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis	Apr. 16	GL
Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with Sepsis	Apr. 11	GL
Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis	Apr. 11	GL
Enlivex Therapeutics : Notes to Consolidated Financial Statements - Form 6-K	Mar. 29	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Enlivex Therapeutics Ltd. Deutsche Boerse AG

Equities

1BT

IL0011319527

Press Releases

Filters